News

TB Alliance Drug,TBA-354, enters Phase I Clinical Trials

19 Feb 2015
by Working Group
Announcements TB Drug Development TB R&D Spotlight Interviews TB Treatment Uncategorized
clinical trials press tb alliance treatment

TB Alliance announced that its compound TBA-354 has started Phase I clinical trials. This announcement is particularly exciting given that TBA-354 is the first TB drug to enter Phase I trials since 2009. TBA-354 is a next generation compound in the nitroimidazole class, which also includes pretomanid (PA-824). This class of drugs is known to be effective against drug-sensitive and drug-resistant tuberculosis and currently pretomanid is being tested in several clinical trials.

To read the official press release from TB Alliance, click here.

Additional Links

WGND TBA-354 Profile

Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis

More News
22 Jul 2024

With NIH Funding, A New Consortium Aims to Improve TB Treatment

The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024

WHO Released Its Updated Bacterial Priority Pathogens List

On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024

Most Robust TB Drug Pipeline in History

For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...